Oct. 13 (Bloomberg) -- Teva Pharmaceutical Industries Ltd. won European approval for its $6.2 billion acquisition of Cephalon Inc., the final regulatory hurdle for the deal, after agreeing to divest the right to sell a generic drug in France.
The companies plan to close the deal tomorrow, Teva and Cephalon said today in a statement.
As a condition of European Commission approval, Petach Tikva, Israel-based Teva must divest Cephalon’s marketing rights in France for a generic version of the $1.1 billion narcolepsy drug Provigil. Teva also agreed to grant the purchaser “certain additional rights with respect to the entire European Economic Area, including a covenant not to sue,” the companies said.
U.S. regulators approved Teva’s purchase of Frazer, Pennsylvania-based Cephalon last week after Teva agreed to let Par Pharmaceutical Cos. market modafinil, the generic form of Provigil, for a year. The Federal Trade Commission also required Teva to sell Par its rights to generic versions of a fentanyl lozenge for cancer pain and an extended release form of the muscle relaxant Flexeril.
--With assistance from Michelle Fay Cortez in Minneapolis. Editor: Andrew Pollack, Bruce Rule
To contact the reporter on this story: Molly Peterson in Washington at email@example.com
To contact the editor responsible for this story: Reg Gale at firstname.lastname@example.org